Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
05/17/2012 | 07:41pm CET
   By Peter Loftus 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
03:29pJOHNSON & JOHNSON : Corporate Presenter Harriet Stein Promotes Mindful Leadershi..
03/20JOHNSON & JOHNSON : Change in Directors or Principal Officers, Financial Stateme..
03/20JOHNSON & JOHNSON : Dominic J. Caruso to Retire as Chief Financial Officer of Jo..
03/20NEW RESEARCH REPORT ON INTERNET OF T : Global Internet of Things for Diabetes Ma..
03/20JOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
03/20Global Brands Divided Over Transparency Efforts to Tackle Deforestation for P..
03/20JOHNSON & JOHNSON : FDA shares data from first drug in transparency pilot
03/20JOHNSON & JOHNSON : unveils plans for second turbine at Limerick facility
03/20JOHNSON & JOHNSON : Rep. Harold Rogers (R-KY) News Release
03/19JOHNSON & JOHNSON : Janssen Announces U.S. FDA Breakthrough Therapy Designation ..
More news
News from SeekingAlpha
10:29aFDA OKs Sun Pharma's Ilumya for plaque psoriasis 
05:25aGeron's Imetelstat Hits A Grand Slam, But The Rally Is Just Beginning 
03/20Johnson & Johnson finance chief to retire in September 
03/2010 Dividend Growth Stocks For March 2018 
03/20JOHNSON & JOHNSON : Dividend Hike Ahead 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,77%
P/E ratio 2018 18,08
P/E ratio 2019 16,97
EV / Sales 2018 4,46x
EV / Sales 2019 4,12x
Capitalization 349 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 15%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.79%349 387
PFIZER1.55%216 268
NOVARTIS-5.90%213 387
ROCHE HOLDING LTD.-10.99%199 363
MERCK AND COMPANY-2.90%147 293
AMGEN4.97%131 539